Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis

Fig. 3

Forest plot of outcomes of IgAN patients treated with MMF monotherapy or corticosteroid monotherapy or placebo. Main analysis and subgroup analysis by human race of remission rate (a), urinary protein reduction (b), serum creatinine doubling rate (c), progression to ESRD rate (d) and side effect rate (e) are provided. ESRD, end-stage renal disease; IgAN, immunoglobulin A nephropathy; MMF, mycophenolate mofetil

Back to article page